Revelation Biosciences, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 2.2 million compared to USD 1.21 million a year ago. Basic loss per share from continuing operations was USD 8.33 compared to USD 15.61 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.06 USD | -6.36% | -13.08% | -86.29% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-86.29% | 3.36M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- REVB Stock
- News Revelation Biosciences, Inc.
- Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023